Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$29.49

-0.15 (-0.51%)

10:09
12/22/16
12/22
10:09
12/22/16
10:09

JPMorgan sees 2017 as 'tale of two halves' for Sarepta

Looking to 2017, JPMorgan analyst Anupam Rama believes Sarepta Therapeutics' (SRPT) shares could be range-bound in the first half of the year as Wall Street re-calibrates to a more appropriate Exondys 51 launch trajectory. However, the analyst says Sarepta could be poised for a rebound in the second half of 2017 as it works with payers and provides greater clarity. POISED FOR A REBOUND: In a research note this morning, JPMorgan's Rama initiated coverage of Sarepta with an Overweight rating and $40 price target. The analyst noted that the stock is down over 50% since the September approval of the company's Exondys 51 for the treatment of Exon 51 Duchenne muscular dystrophy. The analyst also sees overall negative sentiment in the market related to the company's commercial launch dynamics. Although physicians showed a "strong desire" to transition patients to therapy, some payer discussions called into question the clinical benefit of Exondys 51 overall, with others noting it would be difficult to limit reimbursement given unmet need in Duchenne muscular dystrophy, he pointed out. While Rama believes it could take two quarters for Wall Street to re-calibrate to a more appropriate launch trajectory, keeping Sarepta's shares range-bound/volatile in the first half of 2017, he told investors that the stock could be poised for a rebound given greater clarity on market dynamics, time to work with payers and pipeline data on the horizon. "Patience will be required" for Sarepta investors, the analyst contended. WHAT'S NOTABLE: Yesterday, Leerink analyst Joseph Schwartz lowered his price target for Sarepta to $33 from $55 as he continues to see a "significant likelihood" that the launch metrics that the company will announce in early January may disappoint Wall Street, where revenue estimates are still aggressive relative to the number of patients that he believes are receiving reimbursement for Exondys 51. The analyst reiterated a Market Perform rating on the shares. PRICE ACTION: In morning trading, shares of Sarepta have gained about 1.5% to $29.91.

SRPT Sarepta
$29.49

-0.15 (-0.51%)

12/16/16
RBCM
12/16/16
NO CHANGE
Target $98
RBCM
Top Pick
RBC lowered target for Sarepta still represents 220% upside
After hosting a conference call with two "well-known" neurologists who specialize in Duchenne muscular dystrophy, RBC Capital analyst Simos Simeonidis lowered his price target for Sarepta Therapeutics to $98 from $106. The new target, however, still represents over 220% upside from current levels. Sarepta in early trading is down 28c to $30.25. Both neurologists were "positive" on Sarepta's EXONDYS 51 and have both prescribed the drug, with one physician now treating patients who have received payor approval, Simeonidis tells investors in a research note. The physicians discussed the issues facing the EXONDYS 51 launch, namely "initial pushback, roadblocks and frustrating delays by payors," but they view the obstacles as "expected" and in-line "for a new drug launch in a rare disease," the analyst writes. Simeonidis points out that both neurologists were optimistic on both the eventual outlook for coverage and on the wide use of EXONDYS 51. Despite lowering his Q4 and 2017 sales numbers for the drug in addition to his price target, Simeonidis still believes EXONDYS has the opportunity to capture significant market share in DMD. He reiterated an Outperform rating on Sarepta in his research note titled, "DMD KOLs call: Payors will delay, delay, delay...but they will end up approving."
12/20/16
GSCO
12/20/16
INITIATION
Target $40
GSCO
Neutral
Sarepta initiated with a Neutral at Goldman
Goldman analyst Salveen Richter initiated Sarepta with a Neutral and a $40 price target.
12/21/16
LEER
12/21/16
NO CHANGE
Target $33
LEER
Market Perform
Sarepta price target lowered to $33 from $55 at Leerink
Leerink analyst Joseph Schwartz lowered his price target for Sarepta to $33 from $55 as he continues to see a "significant likelihood" that the launch metrics that the company will announce in early January may disappoint the street, where revenue estimates are still aggressive relative to the number of patients that he believes are receiving reimbursement for Exondys 51. The analyst reiterates a Market Perform rating on the shares.
12/22/16
JPMS
12/22/16
INITIATION
Target $40
JPMS
Overweight
Sarepta initiated with an Overweight at JPMorgan
JPMorgan analyst Anupam Rama started Sarepta Therapeutics with an Overweight rating and $40 price target. The stock is down over 50% since the September approval of Exondys 51 for the treatment of Exon 51 Duchenne muscular dystrophy, Rama tells investors in a research note. The analyst believes that while shares could be range-bound in the first half of 2017 amid a "conservative launch trajectory" relative to consensus expectations, Sarepta "could be poised for a rebound" in the second half of the year as it works work with payers and provides greater clarity. He thinks "patience will be required" for Sarepta investors.

TODAY'S FREE FLY STORIES

16:37
11/24/17
11/24
16:37
11/24/17
16:37
General news
Money Supply M2 Weekly Change data reported »

Week of 11/13 Money…

16:37
11/24/17
11/24
16:37
11/24/17
16:37
General news
Fed Balance Sheet Level data reported »

Week of 11/22 Fed Balance…

$NSD

NASDAQ Market Internals

16:17
11/24/17
11/24
16:17
11/24/17
16:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

16:16
11/24/17
11/24
16:16
11/24/17
16:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:15
11/24/17
11/24
16:15
11/24/17
16:15
General news
Breaking General news story  »

Week of 11/13 Money…

16:15
11/24/17
11/24
16:15
11/24/17
16:15
General news
Breaking General news story  »

Week of 11/22 Fed Balance…

RIC

Richmont Mines

16:01
11/24/17
11/24
16:01
11/24/17
16:01
Hot Stocks
Breaking Hot Stocks news story on Richmont Mines »

Richmont Mines trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGLN

Magellan Health

$83.65

0.35 (0.42%)

15:18
11/24/17
11/24
15:18
11/24/17
15:18
Conference/Events
Magellan Health to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

SGMS

Scientific Games

$52.00

-0.2 (-0.38%)

15:17
11/24/17
11/24
15:17
11/24/17
15:17
Conference/Events
Scientific Games to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

15:17
11/24/17
11/24
15:17
11/24/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
11/24/17
11/24
15:16
11/24/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:17
11/24/17
11/24
14:17
11/24/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
11/24/17
11/24
14:16
11/24/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$21.07

0.44 (2.13%)

, WMT

Wal-Mart

$96.62

0.21 (0.22%)

13:29
11/24/17
11/24
13:29
11/24/17
13:29
General news
On The Fly: Top stock stories for Friday »

Stocks on Wall Street…

M

Macy's

$21.07

0.44 (2.13%)

WMT

Wal-Mart

$96.62

0.21 (0.22%)

TGT

Target

$55.88

-1.61 (-2.80%)

BASFY

BASF

$27.39

-0.13 (-0.47%)

TEVA

Teva

$13.70

0.22 (1.63%)

CBS

CBS

$56.54

0.3 (0.53%)

DISH

Dish

$50.43

0.39 (0.78%)

ASX

Advanced Semiconductor

$7.07

0.76 (12.04%)

SPIL

Siliconware Precision

$7.94

-0.05 (-0.63%)

QD

Qudian

$12.22

-3.93 (-24.33%)

BABA

Alibaba

$191.19

1.35 (0.71%)

VIPS

Vipshop

$8.14

-0.3 (-3.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Nov

  • 20

    Feb

  • 18

    Mar

AFL

Aflac

$85.00

-0.05 (-0.06%)

13:26
11/24/17
11/24
13:26
11/24/17
13:26
Conference/Events
Aflac to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

GBL

GAMCO Investors

, WTS

Watts Water

$72.65

0.15 (0.21%)

13:26
11/24/17
11/24
13:26
11/24/17
13:26
Hot Stocks
Breaking Hot Stocks news story on GAMCO Investors, Watts Water »

Gabelli reports 6.69%…

GBL

GAMCO Investors

WTS

Watts Water

$72.65

0.15 (0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

CC

Chemours

$53.31

0.45 (0.85%)

13:23
11/24/17
11/24
13:23
11/24/17
13:23
Conference/Events
Chemours to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

$NSD

NASDAQ Market Internals

13:17
11/24/17
11/24
13:17
11/24/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
11/24/17
11/24
13:16
11/24/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIMT

Aimmune

$35.74

0.16 (0.45%)

13:09
11/24/17
11/24
13:09
11/24/17
13:09
Conference/Events
Aimmune to hold an investor symposium »

Investor Symposium…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

PN

Patriot National

12:57
11/24/17
11/24
12:57
11/24/17
12:57
Hot Stocks
Breaking Hot Stocks news story on Patriot National »

Patriot National trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCM

Cheetah Mobile

$12.02

-0.4 (-3.22%)

12:55
11/24/17
11/24
12:55
11/24/17
12:55
Options
Cheetah Mobile put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$44.47

0.1828 (0.41%)

12:53
11/24/17
11/24
12:53
11/24/17
12:53
Conference/Events
General Motors holds an investor an analyst webcast »

Management hosts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

  • 09

    Jan

  • 16

    Jan

12:45
11/24/17
11/24
12:45
11/24/17
12:45
General news
Breaking General news story  »

Week of 11/24…

EBAY

eBay

$35.94

-0.02 (-0.06%)

, OSTK

Overstock.com

$61.05

0.6 (0.99%)

12:43
11/24/17
11/24
12:43
11/24/17
12:43
Periodicals
Adobe: Black Friday online sales up 18.4% y/y as of 10:00 am ET, CNBC says »

According to Adobe…

EBAY

eBay

$35.94

-0.02 (-0.06%)

OSTK

Overstock.com

$61.05

0.6 (0.99%)

AMZN

Amazon.com

$1,156.16

16.67 (1.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 18

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.